Clinical Trial Update: Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Epirubicin with Docetaxel given together (ET) versus Epirubicin followed by Docetaxel (E/T) in node-negative high-risk breast cancer h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED